Fig. 2: The prognostic role of baseline pTcd8+cd28- in HER2 + MBC patients regarding first-line PFS. | British Journal of Cancer

Fig. 2: The prognostic role of baseline pTcd8+cd28- in HER2 + MBC patients regarding first-line PFS.

From: Persistence of peripheral CD8 + CD28− T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer

Fig. 2

Determine the prognostic role of pTcd8+cd28− in training set (a) and retest in the validation set (b). Cox regression analysis was performed for pTcd8+cd28−, including other factors contributing to the PFS. The HR values for each factor derived from the multivariate analysis are also presented (c). The prognostic role of pTcd8+cd28− in the chemotherapy plus trastuzumab subgroup (d), in the chemotherapy plus trastuzumab & pertuzumab subgroup (e), in the chemotherapy plus TKIs subgroup (f) and in chemotherapy-alone subgroup (g); The prognostic role of pTcd8+cd28− in patients who received anti-HER2 based therapy (h). pTcd8+cd28− peripheral CD8 + CD28- T cell, TKIs tyrosine kinase inhibitors.

Back to article page